Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | June 05, 2026 | June 09, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 30,000 · Balance 30,000 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2036-06-05 | Direct | 60,000 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 60,000 · Balance 60,000 F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
MYRIAD GENETICS INC
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 191,842 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 59,701 · Balance 191,842 F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 22:42 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001610717-26-000204 · form4.xml · derivative · entry 2 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 22:42 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000204 · form4.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 59,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001788981-26-000002 · wk-form4_1780691122.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,842 F1 · shares: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 22:50 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001610717-25-000228 · form4.xml · derivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:04 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 49,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-029974 · wk-form4_1749240285.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,141 F1 · shares: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027333 · wk-form4_1717793661.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,345 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:47 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001610717-24-000288 · form4.xml · derivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2034-06-03 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 3, 2024, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:48 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 6,200 | $25.30 | $156,860.00 |
DisclosureSEC source: 0001788981-24-000002 · wk-form4_1715809662.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,650 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.30 to $25.39, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 38,250 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001610717-23-000120 · form4.xml · derivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,250 Underlying: Common Stock · 38,250 shares Expires 2033-06-07 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from June 7, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:07 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001788981-23-000002 · wk-form4_1685743652.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,850 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 21:26 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 17,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-016220 · wf-form4_165429159331764.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,699 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the Date of Grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 01:19 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001567619-22-002564 · doc1.xml · derivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from February 2, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:02 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 12,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001788981-21-000002 · edgardoc.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,424 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 22:24 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001788981-20-000003 · edgardoc.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,576 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 18:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 11,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001788981-19-000004 · edgardoc.xml · nonDerivative · entry 1 Newcomer Lee Nisley · CIK 0001788981 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,687 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.